Financial Performance Overview
Gufic Biosciences Limited reported mixed financial results for FY26 with standalone revenue growth of 14.7% to ₹940.48 crores but net profit declining 9.7% to ₹63.15 crores. The profit decline was primarily attributed to increased depreciation (₹30.83 crores vs ₹21.06 crores) and finance costs (₹36.61 crores vs ₹24.52 crores) related to the new Indore manufacturing facility. Consolidated performance showed similar trends with revenue of ₹944.01 crores and net profit of ₹64.21 crores.
Operational Highlights and Expansion
The company's Indore manufacturing facility reached EBITDA breakeven in Q4 FY26 and successfully completed EU GMP audit, awaiting certification for European market access. Exports contribution increased significantly to 23.07% of turnover from 20.17% in FY25, supported by 63 product registrations in international markets. The company launched 18+ products across domestic and export markets and invested ₹11.59 crores in capital expenditure and ₹10.49 crores in R&D.
Balance Sheet and Financial Position
Total borrowings increased to ₹385.16 crores (from ₹310.37 crores) secured by factory assets and personal guarantees. Inventory levels surged 49.6% to ₹324.47 crores while trade receivables stood at ₹297.40 crores. Cash position improved to ₹60.32 crores from ₹14.91 crores. The company maintained strong credit ratings of CRISIL A-/Stable and ICRA A-(Stable). Key ratios showed pressure with Return on Net Worth declining to 9.51% from 11.63% and Interest Coverage Ratio falling to 4.18 from 5.71.
Corporate Actions and Governance
The Board recommended a final dividend of ₹0.10 per equity share (10% on face value) with record date of August 28, 2026 and payment on or after September 9, 2026. The company allotted 5,000 equity shares under ESOP 2023 scheme at ₹2 per share. CSR expenditure exceeded requirements at ₹242.05 lakhs against mandated ₹211.04 lakhs. The 42nd AGM is scheduled for September 4, 2026 through video conference to approve accounts, dividend, and director appointments.
Subsidiaries and Related Parties
The consolidated entity includes subsidiaries Gufic UK Limited, Veira Life FZE (commenced operations), Gufic Ireland Limited, and Gufic Prime Private Limited (60% holding). Significant related party transactions included rent payments of ₹4.68 crores to group entities and security deposits of ₹3.86 crores. The parent company contributed 99.71% to consolidated net assets and 98.34% to consolidated profit.
Regulatory Compliance and Outlook
The company maintained compliance with SEBI listing regulations, MCA requirements including SAP audit trail implementation, and transferred unpaid dividend and shares to IEPF. Forward outlook focuses on scaling the new facility, international market expansion, product portfolio enhancement, and backward integration into complex APIs despite facing regulatory compliance risks, competition pressures, and foreign exchange fluctuations.